Nitrendipine
As of the edition of 20 October 2026, Nitrendipine is a small molecule: marketed, first approved in 2002 (ES); acts on CACNA1C, CACNA1D and CACNA1F and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Eneas
- First approved
- 2 January 2002 (ES)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ferrer Internacional
- Registered trials
- 5, 0 stopped early
- Disease areas
- Heart and blood vessels; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 4 | 3 | 0 | 0 | 0 |
| All trials | 5 |